The FDA has approved atezolizumab and hyaluronidase-tqjs as a subcutaneous injection for adults with various types of cancer. This is the first programmed death–ligand 1 inhibitor to be approved for subcutaneous administration. The approval was based on a trial showing similar outcomes between subcutaneous and intravenous administration. The recommended dose is one injection every 3 weeks in the thigh. Common side effects include fatigue, musculoskeletal pain, cough, dyspnea, and decreased appetite. Overall, this approval provides a more convenient option for patients, according to LUNGevity Foundation. Sharon Worcester, a medical journalist, covers oncology news and can be contacted at sworcester@mdedge.com.
Source link
FDA OKs Subcutaneous Atezolizumab for Multiple Cancers
